Champions Oncology CSBR

NASDAQ CSBR

$5.01 -0.09 (-1.76%)

As of: Sep 9, 2026 · 3:58 PM EDT

Key Stats

Market Cap69.16 Mn

P/E-58.86

P/S1.16

Div. Yield0.00

Revenue Growth (1y) (Qtr)11.98

Add ratio to table…

About

Champions Oncology, Inc. is a technology enabled research organization that creates solutions for drug discovery and development in the oncology sector. The company operates a research center that combines computational and experimental platforms to serve biopharmaceutical clients. At the heart of its offering is a proprietary bank of Patient Derived Xenograft models known as the TumorBank. This resource supports preclinical studies data licensing and software services. The…

Champions Oncology generates revenue through four primary lines. First it sells research services that use its TumorBank and related platforms to run preclinical studies for pharmaceutical and biotechnology companies. Second it licenses access to its PDX model data and associated multi omic datasets. Third it offers a software as a service platform called Lumin Bioinformatics that provides analytics and artificial intelligence tools built on its Datacenter. Fourth it pursues internal drug discovery and development programs that may yield novel oncology therapeutics for future partnership or outlicensing. The research services business has historically been the largest contributor to total revenue.

The company operates through the following segments: Translational Oncology Solutions Research Services Data Licenses Software as a Service Business and Drug Discovery and Development.

Translational Oncology Solutions (TOS) Business Research Services provides preclinical study contracts to pharmaceutical and biotechnology firms. The service uses the company’s TumorBank of Patient Derived Xenograft models to run in vivo and ex vivo experiments that measure drug response and resistance. Studies may include bioinformatics analysis to reveal genetic signatures linked to sensitivity or resistance. The segment also offers support for target identification patient selection combination strategy development and biomarker hypothesis generation. Work is conducted in both non regulatory and Good Clinical Regulatory Practice environments. Typical project fees range from one hundred twenty five thousand dollars to five hundred thousand dollars with a growing share in the higher band. The business has served approximately five hundred different clients over the past ten years and enjoys a high rate of repeat business across North America Europe and Asia.
Data Licenses provide access to the company’s proprietary PDX model data and associated multi omic datasets. The licensed material includes genomics transcriptomics proteomics phosphoproteomics datasets clinical drug response measurements in vivo drug response readings and linked patient information. The Datacenter combines this internal data with approximately twenty thousand publicly available datasets to create a comprehensive oncology knowledge base. Customers obtain licenses to query the data for target discovery biomarker development and preclinical planning. Revenue from this line is generated through annual or multi year agreements based on data volume and access level.
The Software as a Service Business centers on the Lumin Bioinformatics platform which is offered on an annual subscription basis. Lumin integrates the company’s Datacenter with analytics and artificial intelligence tools to support computational cancer research. Users can generate biomarker hypotheses uncover mechanisms of therapeutic resistance and guide further preclinical evaluation. The service is marketed to academic investigators pharmaceutical researchers and biotechnology scientists who seek to leverage the Datacenter for hypothesis generation and data driven decision making.
The Drug Discovery and Development Business leverages the company’s computational and experimental platforms to identify and validate novel oncology therapeutics. The effort concentrates on three areas targeted therapy with drug conjugates immune oncology and cell therapy. Projects begin with Datacenter driven target identification followed by experimental validation using proprietary pharmacology and analytical platforms. Research and development teams are kept separate from the service divisions to protect intellectual property. The business maintains a pipeline of targets at various stages with some advancing toward therapeutic development. Commercialization options include partnership licensing or potential spin out transactions.

Champions Oncology occupies a niche position in the oncology research services market where it combines a large living TumorBank with deep molecular characterization and a proprietary software platform. The company competes with larger contract research organizations that offer generic preclinical testing but lack its specialized PDX resources. In the data licensing and SaaS spaces it faces competition from public genomic databases and various bioinformatics tools yet differentiates itself through the longitudinal living nature of its model bank and its integrated analytics. In the drug discovery arena it contends with established biopharmaceutical firms but leverages its internal discovery engine to generate early stage assets that may attract partnership interest. Competitive advantages include the scale and depth of the TumorBank the richness of the Datacenter the ability to move seamlessly from data insight to experimental validation and a focused expertise in oncology specific models.

The company serves a diverse group of clients primarily consisting of pharmaceutical and biotechnology enterprises that seek preclinical testing data licenses or computational tools for oncology drug development. It also works with academic research institutions and nonprofit organizations that use its SaaS platform and data licenses for basic and translational science. While the filing does not disclose individual customer names it notes a broad geographic reach across North America Europe and Asia and a high rate of repeat business among its core pharma and biotech clients.

Investment Thesis

▲ Bull case

Champions Oncology is positioned to leverage its differentiated PDX Bank and expanding radiopharmaceutical capabilities to capture increasing demand for precision oncology services, particularly as pharmaceutical companies prioritize clinically translatable models in early drug development. Despite quarterly revenue fluctuations driven by the lumpy nature of study completion timing, the company demonstrated robust underlying strength with core study revenue growing 32% year-over-year to a record $16.6 million in Q3 FY26, reflecting successful conversion of booked work and operational scalability without proportional headcount increases. This operating leverage, combined with management’s disciplined approach to reinvesting service profits into high-potential adjacent platforms like data and Corellia, suggests the core business is not only resilient but capable of funding future growth internally. The stabilization of customer budgets and sustained commercial engagement indicate that the recent revenue normalization is a temporary phase in an otherwise durable demand environment, setting the stage for accelerated services revenue as backlog converts consistently through the fiscal year.
The nascent data platform, though not yet a quarterly revenue contributor, is showing tangible early traction with multiple 6-figure deals closed in Q3 FY26 expected to recognize in Q4, alongside continued progress on the large data deal announced in Q3 FY25. Management emphasized that customer engagement remains strong, particularly around integrating deep biological annotation with clinically relevant tumor models—a unique value proposition that addresses a critical gap in oncology R&D. This deliberate, relationship-driven approach to building the data business is laying the foundation for diversified, recurring revenue streams and larger enterprise deals as trust and data utility scale. Since the company is not aggressively pushing this narrative but instead quietly advancing milestones, the market may be underestimating the inflection point where the data platform transitions from investment phase to meaningful revenue contributor, potentially becoming a margin-accretive growth driver by FY27 as predicted.
Corellia, the wholly owned therapeutic discovery subsidiary, represents an asymmetric upside opportunity that is currently underappreciated due to its pre-revenue status and lack of near-term earnings impact. The subsidiary continues to generate compelling data attracting active interest from venture capital and licensing partners, with management confirming that ongoing discussions are strengthening the investment case despite the challenging biotech funding environment. Crucially, Champions has already incorporated Corellia’s funding into its FY27 budgeting assumptions, meaning any successful external financing would redeploy currently allocated EBITDA toward other growth initiatives or directly to the bottom line—creating a potential dual benefit of reduced cash burn and accelerated profitability. Since the market tends to devalue optionality in early-stage biotech ventures, the probability-weighted value of Corellia’s potential licensing deals, milestones, or spin-out may not be reflected in the current stock price, offering a hidden catalyst that could materialize with minimal dilution as management has explicitly avoided equity issuance to fund this initiative.

Champions Oncology is positioned to leverage its differentiated PDX Bank and expanding radiopharmaceutical capabilities to capture increasing demand for precision oncology services, particularly as pharmaceutical companies prioritize clinically translatable models in early drug development. Despite quarterly revenue fluctuations driven by the lumpy nature of study completion timing, the company demonstrated robust underlying strength with core study revenue growing 32% year-over-year to a record $16.6 million in Q3 FY26, reflecting successful conversion of booked work and operational scalability without proportional headcount increases. This operating leverage, combined with management’s disciplined approach to reinvesting service profits into high-potential adjacent platforms like data and Corellia, suggests the core business is not only resilient but capable of funding future growth internally. The stabilization of customer budgets and sustained commercial engagement indicate that the recent revenue normalization is a temporary phase in an otherwise durable demand environment, setting the stage for accelerated services revenue as backlog converts consistently through the fiscal year.
The nascent data platform, though not yet a quarterly revenue contributor, is showing tangible early traction with multiple 6-figure deals closed in Q3 FY26 expected to recognize in Q4, alongside continued progress on the large data deal announced in Q3 FY25. Management emphasized that customer engagement remains strong, particularly around integrating deep biological annotation with clinically relevant tumor models—a unique value proposition that addresses a critical gap in oncology R&D. This deliberate, relationship-driven approach to building the data business is laying the foundation for diversified, recurring revenue streams and larger enterprise deals as trust and data utility scale. Since the company is not aggressively pushing this narrative but instead quietly advancing milestones, the market may be underestimating the inflection point where the data platform transitions from investment phase to meaningful revenue contributor, potentially becoming a margin-accretive growth driver by FY27 as predicted.
Corellia, the wholly owned therapeutic discovery subsidiary, represents an asymmetric upside opportunity that is currently underappreciated due to its pre-revenue status and lack of near-term earnings impact. The subsidiary continues to generate compelling data attracting active interest from venture capital and licensing partners, with management confirming that ongoing discussions are strengthening the investment case despite the challenging biotech funding environment. Crucially, Champions has already incorporated Corellia’s funding into its FY27 budgeting assumptions, meaning any successful external financing would redeploy currently allocated EBITDA toward other growth initiatives or directly to the bottom line—creating a potential dual benefit of reduced cash burn and accelerated profitability. Since the market tends to devalue optionality in early-stage biotech ventures, the probability-weighted value of Corellia’s potential licensing deals, milestones, or spin-out may not be reflected in the current stock price, offering a hidden catalyst that could materialize with minimal dilution as management has explicitly avoided equity issuance to fund this initiative.

▼ Bear case

Champions Oncology’s reported financial resilience masks underlying volatility in its core services business, where quarterly revenue remains highly sensitive to the timing of study completion and customer budget cycles, creating unpredictable fluctuations that hinder consistent growth visibility. Although core study revenue grew 32% year-over-year in Q3 FY26, this was largely driven by the conversion of previously booked work and favorable study completion timing—a non-recurring boost that management acknowledged will normalize in the near term, suggesting the underlying demand momentum may be weaker than the headline growth implies. The company’s reliance on backlog conversion to offset the absence of data revenue (which contributed $4.5 million in the prior year period) highlights a structural vulnerability: without consistent new booking inflow, services revenue could decline once the current pipeline is exhausted, especially if pharmaceutical clients delay or scale back oncology R&D spending amid macroeconomic pressures or shifting investment priorities.
While the data platform is presented as a long-term growth lever, its current contribution remains negligible and highly uncertain, with no data revenue recognized in Q3 FY26 despite incremental progress on deals. The 6-figure transactions cited as early traction are insufficient to meaningfully impact financials at scale, and the continued dependence on a single large deal from Q3 FY25 for near-term expectations raises concerns about customer concentration and the platform’s ability to diversify revenue sources. Furthermore, the extended sales cycles typical of data and analytics agreements in biotech—often requiring validation, integration, and trust-building over multiple quarters—mean that meaningful revenue recognition may slip beyond management’s optimistic FY27 timeline, leaving the platform as a persistent drag on profitability through continued R&D and sales investments without commensurate returns.
Corellia’s potential value remains highly speculative and contingent on external financing in a challenging biotech funding environment, where venture capital is increasingly risk-averse and focused on later-stage, de-risked opportunities. Management’s admission that they lack a specific timing estimate for an external round, coupled with acknowledgment that these processes “take time,” suggests significant uncertainty around when—or if—Corellia will achieve funding milestones that would trigger EBITDA redeployment or bottom-line relief. Until such an event occurs, Champions will continue to absorb the full cost of funding Corellia internally, suppressing adjusted EBITDA and limiting cash available for other initiatives or shareholder returns. Given the subsidiary’s pre-revenue status and the competitive, capital-intensive nature of target discovery, the likelihood of a near-term financing event appears low, meaning the market may be overestimating the near-term benefit of this growth vector while underappreciating the ongoing opportunity cost of sustaining it without external validation.

Champions Oncology’s reported financial resilience masks underlying volatility in its core services business, where quarterly revenue remains highly sensitive to the timing of study completion and customer budget cycles, creating unpredictable fluctuations that hinder consistent growth visibility. Although core study revenue grew 32% year-over-year in Q3 FY26, this was largely driven by the conversion of previously booked work and favorable study completion timing—a non-recurring boost that management acknowledged will normalize in the near term, suggesting the underlying demand momentum may be weaker than the headline growth implies. The company’s reliance on backlog conversion to offset the absence of data revenue (which contributed $4.5 million in the prior year period) highlights a structural vulnerability: without consistent new booking inflow, services revenue could decline once the current pipeline is exhausted, especially if pharmaceutical clients delay or scale back oncology R&D spending amid macroeconomic pressures or shifting investment priorities.
While the data platform is presented as a long-term growth lever, its current contribution remains negligible and highly uncertain, with no data revenue recognized in Q3 FY26 despite incremental progress on deals. The 6-figure transactions cited as early traction are insufficient to meaningfully impact financials at scale, and the continued dependence on a single large deal from Q3 FY25 for near-term expectations raises concerns about customer concentration and the platform’s ability to diversify revenue sources. Furthermore, the extended sales cycles typical of data and analytics agreements in biotech—often requiring validation, integration, and trust-building over multiple quarters—mean that meaningful revenue recognition may slip beyond management’s optimistic FY27 timeline, leaving the platform as a persistent drag on profitability through continued R&D and sales investments without commensurate returns.
Corellia’s potential value remains highly speculative and contingent on external financing in a challenging biotech funding environment, where venture capital is increasingly risk-averse and focused on later-stage, de-risked opportunities. Management’s admission that they lack a specific timing estimate for an external round, coupled with acknowledgment that these processes “take time,” suggests significant uncertainty around when—or if—Corellia will achieve funding milestones that would trigger EBITDA redeployment or bottom-line relief. Until such an event occurs, Champions will continue to absorb the full cost of funding Corellia internally, suppressing adjusted EBITDA and limiting cash available for other initiatives or shareholder returns. Given the subsidiary’s pre-revenue status and the competitive, capital-intensive nature of target discovery, the likelihood of a near-term financing event appears low, meaning the market may be overestimating the near-term benefit of this growth vector while underappreciating the ongoing opportunity cost of sustaining it without external validation.

Product and Service Breakdown of Revenue (2026)

Peer group

Peer Comparison

Companies in the Contract Research

S.No.	Ticker	Company	match	Market Cap	P/E	P/S	Total Debt (Qtr)
1	IQV	Iqvia Holdings Inc.	primary	42.77 Bn	32.40	2.52	16.00 Bn
2	MEDP	Medpace Holdings, Inc.	primary	16.50 Bn	33.58	5.93	-
3	CRL	Charles River Laboratories International, Inc.	primary	13.37 Bn	-56.26	3.34	2.62 Bn
4	ICLR	Icon Plc	primary	12.49 Bn	16.05	1.51	3.39 Bn
5	FTRE	Fortrea Holdings Inc.	primary	1.58 Bn	-18.59	0.59	1.05 Bn
6	EVO	Evotec SE	primary	0.64 Bn	-	-	0.55 Bn
7	DNA	Ginkgo Bioworks Holdings, Inc.	primary	0.42 Bn	-1.45	3.78	-
8	CSBR	Champions Oncology, Inc.	primary	0.07 Bn	-58.86	1.16	-

Champions Oncology CSBR

About

Investment Thesis

Product and Service Breakdown of Revenue (2026)

Peer Comparison

Create an account

Sign In

Reset Password